Table 3 |
|||
|
The association of response to preoperative CAF treatment and patients' clinical and pathological characteristics with expression levels of Skp2 and p27Kip1 |
|||
|
Characteristics |
Response |
P value |
|
|
|
|||
|
+ |
- |
||
|
|
|||
|
Age (years) |
|||
|
>50 |
8 |
17 |
0.13 |
|
<50 |
9 |
6 |
0 |
|
Tumor grade |
|||
|
G1 + G2 |
16 |
8 |
|
|
G3 |
4 |
12 |
0.010* |
|
Primary tumor |
|||
|
T2 |
5 |
2 |
0.151 |
|
T3 |
7 |
13 |
|
|
T4 |
8 |
5 |
|
|
Lymph node status |
|||
|
Positive |
16 |
9 |
0.022* |
|
Negative |
4 |
11 |
|
|
Stage |
|||
|
IIA |
3 |
1 |
0.289 |
|
IIB |
2 |
6 |
|
|
IIIA |
7 |
8 |
|
|
IIIB |
8 |
5 |
|
|
Estrogen receptor status |
|||
|
Positive |
15 |
9 |
0.053 |
|
Negative |
5 |
11 |
|
|
Progesterone receptor status |
|||
|
Positive |
14 |
8 |
0.057 |
|
Negative |
6 |
12 |
|
|
HER-2 receptor status |
|||
|
Positive |
6 |
3 |
0.212 |
|
Negative |
14 |
17 |
|
|
p27Kip1 |
|||
|
High |
19 |
16 |
0.037* |
|
Low |
1 |
4 |
|
|
Skp2 |
|||
|
High |
1 |
16 |
0.0001* |
|
Low |
19 |
4 |
|
|
|
|||
|
*P value < 0.05 was considered statistically significant. +, ≥ 50% reduction in tumor size; -, no response or <50% reduction in tumor size; KIP, kinase inhibitor protein; Skp2, S-phase kinase protein 2. |
|||
|
Davidovich et al. Breast Cancer Research 2008 10:R63 doi:10.1186/bcr2122 |
|||
